MAM
ORKA

Martingale Asset Management’s Oruka Therapeutics ORKA Stock Holding History

Martingale Asset Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Sell
26,727
-16,005
-37% -$1.07M 0.06% 342
2026
Q1 		$2.1M Buy
+42,732
New +$1.49M 0.05% 343

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Martingale Asset Management's ORKA Position: Q2 2026 in Review

Martingale Asset Management reduced its Oruka Therapeutics (ORKA) stake by 37% in Q2 2026, selling an estimated $1.07M and leaving 26,727 shares worth $2.54M. The position accounts for 0.06% of the portfolio, ranked #342.

Martingale Asset Management first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Martingale Asset Management held 26,727 shares of Oruka Therapeutics worth $2.54M as of Q2 2026.
  • Martingale Asset Management sold 16,005 Oruka Therapeutics shares in Q2 2026, an estimated $1.07M.
  • Oruka Therapeutics made up 0.06% of Martingale Asset Management's portfolio in Q2 2026, its #342 holding.
  • Martingale Asset Management first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.